# US 2025/0325544 A1 · Cdk inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0325544 A1
- Document ID: US20250325544A1
- Status: Published application
- Kind: A1
- Application number: 19/210,825
- Filed: 2025-05-16
- Published: 2025-10-23
- Earliest claimed: 2020-05-05
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Zhilong HU; Hu HE; Fei ZHANG; Wenge ZHONG; Xiaotian ZHU
- Web page: https://patentgrep.com/patent/US20250325544A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- C07D 471/04: Ortho-condensed systems
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a compound represented by represented by the following strutural formula: or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

## Claims

### Claim 1

A compound represented by the following structural formula:
or a pharmaceutically acceptable salt or a stereoisomer thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising an effective amount of the compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

A method of treating a cancer comprising administering to a subject in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the cancer is a carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, nose, head and neck, prostate, or skin; a hematopoietic tumor of lymphoid lineage; a hematopoietic tumor of myeloid lineage; thyroid follicular cancer; a tumor of mesenchymal origin; a tumor of the central or peripheral nervous system; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoacanthoma; or Kaposi's sarcoma.

### Claim 4 (depends on 1)

A method of inhibiting activity of a cyclin-dependent kinase (CDK) in a subject, said method comprising administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or a stereoisomer thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the subject has a cancer, such as a carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, nose, head and neck, prostate, or skin; a hematopoietic tumor of lymphoid lineage; a hematopoietic tumor of myeloid lineage; thyroid follicular cancer; a tumor of mesenchymal origin; a tumor of the central or peripheral nervous system; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoacanthoma; or Kaposi's sarcoma.

### Claim 6 (depends on 5)

The method of claim 5, wherein the hematopoietic tumor of lymphoid lineage is leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, B-cell lymphoma, T-cell lymphoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, or Burkett's lymphoma.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the cancer is pRb+ breast cancer, or hormone receptor (HR)-positive (e.g., estrogen receptor positive (ER+), progesterone receptor positive (PR+), or ER+PR+), HER2/neu-negative breast cancer.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cancer is advanced or metastatic or recurrent breast cancer.

### Claim 9 (depends on 8)

The method of claim 8, wherein the breast cancer is in an adult woman, or a postmenopausal woman.

### Claim 10 (depends on 7)

The method of claim 7, further comprising administering a second agent selected from: an aromatase inhibitor, a Selective Estrogen Receptor Modulator (SERM), a pure antiestrogen with no estrogen agonist activity, a compound that temporarily suppresses ovarian function (e.g., estrogen and/or progesterone production) such as a gonadotropin-releasing hormone (GnRH) agonist or a luteinizing hormone-releasing hormone (LH-RH) agonist, a compound that inhibits CYP3A4, or a monoclonal antibody or an antigen-binding fragment thereof against IGF-1/IGF-2.

### Claim 11 (depends on 4)

The method of claim 4, further comprising administering an immune checkpoint inhibitor (such as a PD-1 inhibitor, a PD-L1 inhibitor, or a CTLA-4 inhibitor), a receptor Tyr kinase inhibitor, and/or an antagonist of hormone receptor (such as estrogen receptor).
